Zhitong Finance App News, Shisi Pharmaceutical Group (02005.HK) issued an announcement that the Group's gadobutol has been approved by the China National Drug Administration and registered as an active ingredient for use in marketed formulations. Gadobutrol is a magnetic resonance imaging contrast agent, suitable for adults and children of all ages (including full-term newborns). It is mainly used for contrast-enhanced magnetic resonance imaging (CE-MRI) examinations of all parts of the body (including brain and spinal cord), and contrast-enhanced magnetic resonance angiography (CE-MRA) examinations of various parts of the body.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.